Friday, September 4, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Which Pharma Stock Stands Taller Right Now: LLY or PFE?

View original at finance.yahoo.com
Which Pharma Stock Stands Taller Right Now: LLY or PFE? Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. pharmaceutical leaders, each backed by diversified product portfolios and robust R&D engines…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Orforglipron has potential to be approved and launched in 2026

    80% confidence

  • Pfizer's 2026 EPS expected to decline 4.2% year-over-year

    80% confidence

  • Pfizer's 2026 sales expected to decline 2.1% year-over-year

    80% confidence

  • Lilly's 2026 EPS expected to increase 39.5% year-over-year

    80% confidence

  • Cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027

    80% confidence

  • Loss of exclusivity cliff expected to hurt sales by approximately $1.5 billion in 2026

    80% confidence

  • Lilly is a clear winner over Pfizer due to exceptional growth from Mounjaro and Zepbound, product and pipeline portfolio in high-growth therapeutic areas like obesity, robust growth prospects and bullish analyst sentiment

    80% confidence

  • Metsera candidates expected to generate billions of dollars in peak sales

    80% confidence

  • New and acquired products expected to deliver double-digit growth in 2026

    80% confidence

  • COVID revenues expected to be around $5 billion in 2026, $1.5 billion less than expected sales of about $6.5 billion in 2025

    80% confidence

  • Lilly's 2026 sales expected to increase 22.6% year-over-year

    80% confidence

  • Data readouts from three phase III studies on retatrutide for treating obesity expected in the second half of 2026

    80% confidence

  • Mounjaro and Zepbound are expected to continue to see strong demand in 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com
Which Pharma Stock Stands Taller Right Now: LLY or PFE? — Source | Via News | Via News